EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Polyoxometalates: metallodrug agents for combating amyloid aggregation

Mengmeng Ma, Zhenqi Liu, Huisi Zhao, Haochen Zhang, Jinsong Ren, Xiaogang Qu iD

National Science Review · 13.06.2024 · 11 (7)

DOI: 10.1093/nsr/nwae226 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift National Science Review, online erschienen am 28.06.2024. Verfasst von Mengmeng Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy…. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a devastating neurodegenerative disease that affects ∼50 million people globally. The accumulation of amyloid-β (Aβ) plaques, a predominant pathological feature of AD, plays a crucial role in AD pathogenesis. In this respect, Aβ has been regarded as a highly promising therapeutic target for AD treatment. Polyoxometalates (POMs) are a novel class of metallodrugs being developed as modulators of Aβ aggregation, owing to their negative charge, polarity, and three-dimensional structure. Unlike traditional discrete inorganic complexes, POMs contain tens to hundreds of metal atoms, showcasing remarkable tunability and diversity in nuclearities, sizes, and shapes. The easily adjustable and structurally variable nature of POMs allows for their favorable interactions with Aβ. This mini-review presents a balanced overview of recent progress in using POMs to mitigate amyloidosis. Clear correlations between anti-amyloid activities and structural features of POMs are also elaborated in detail. Finally, we discuss the current challenges and future prospects of POMs in combating AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid inhibitionamyloid-βmetallodrugpolyoxometalate

Autor:innen und Institutionen

  • Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
  • School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China.

ORCID-Profile: Xiaogang Qu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Ma, M., Liu, Z., Zhao, H., Zhang, H., Ren, J., & Qu, X. (2024). Polyoxometalates: metallodrug agents for combating amyloid aggregation. National Science Review, 11(7). https://doi.org/10.1093/nsr/nwae226

Vancouver

Ma M, Liu Z, Zhao H, Zhang H, Ren J, Qu X. Polyoxometalates: metallodrug agents for combating amyloid aggregation. National Science Review. 2024;11(7). doi:10.1093/nsr/nwae226

BibTeX
@article{Ma2024,
  author = {Ma, Mengmeng and Liu, Zhenqi and Zhao, Huisi and Zhang, Haochen and Ren, Jinsong and Qu, Xiaogang},
  title = {Polyoxometalates: metallodrug agents for combating amyloid aggregation},
  journal = {National Science Review},
  year = {2024},
  volume = {11},
  number = {7},
  doi = {10.1093/nsr/nwae226}
}
Kostenlos starten →